Introduction
Over the last decade, there has been a significant increase in the scientific knowledge about cancer, which has accordingly led to the development and increase of interest in new medicines and therapeutic approaches with potential applications in oncology. Activity research and the identification of potential therapeutic and toxic effects of bexarotene-like structures underpin the development of new approaches to the treatment of a number of untreated diseases.
This requires a further and in-depth study of the potential of newly synthesized compounds to produce active metabolites.
Aim
In view of the potential for dermal administration of bexarotene, the potential for toxic metabolism in the skin needs to be investigated.
Materials and Methods
For the purpose the OECD (Q) SAR Application Toolbox was used. It is a software application for evaluating the properties of chemicals based on their molecular structure.
Results
The application of the model for predicting metabolic changes makes it possible to assess the risk based on the chemical structure of the compounds.
Conclusion
The skin metabolic prediction of new hydrazones of third-generation retinoid bexarotene indicates that not one of them predicts binding to DNA or proteins.
Shen D, Yu X, Wu Y, Chen Y, Li G, Cheng F, et al. Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers. Expert Rev Anticancer Ther. 2018;18(5):487-99. doi: 10.1080/14737140.2018.1449648.
Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E,et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem. 1994;37(18):2930-41. doi: 10.1021/jm00044a014.
Alizadeh F, Bolhassani A, Khavari A, Bathaie SZ, Naji T, Bidgoli SA. Retinoids and their biological effects against cancer. Int Immunopharmacol. 2014;18(1):43-9. doi: 10.1016/j.intimp.2013.10.027
Robinson-Rechavi M, Escriva Garcia H, Laudet V. The nuclear receptor superfamily. J Cell Sci. 2003;116(Pt 4):585-6. doi: 10.1242/jcs.00247.
Appleby BS, Cummings JL. Discovering new treatments for Alzheimer's disease by repurposing approved medications. Curr Top Med Chem. 2013;13(18):2306-27. doi: 10.2174/15680266113136660162.
Bomben V, Holth J, Reed J, Cramer P, Landreth G, Noebels J. Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. Neurobiol Aging. 2014;35(9):2091-5. doi: 10.1016/j.neurobiolaging.2014.03.029.
Njar VC, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, et al. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem. 200614(13):4323-40. doi: 10.1016/j.bmc.2006.02.041.
Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. (2001);137(5):581-93.
Simeone AM, Tari AM. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci. 2004;61(12):1475‐84. doi:10.1007/s00018-004-4002-6
Magoulas GE, Bariamis SE, Athanassopoulos CM, Haskopoulos A, Dedes PG, Krokidis MG, et al. Syntheses, antiproliferative activity and theoretical characterization of acitretin-type retinoids with changes in the lipophilic part. Eur J Med Chem. 2011;46(2):721-37. doi: 10.1016/j.ejmech.2010.12.008.
Shirley MA, Wheelan P, Howell SR, Murphy RC. Oxidative metabolism of a rexinoid and rapid phase II metabolite identification by mass spectrometry. Drug Metab Dispos. 1997;25(10):1144-9.
Howell SR, Shirley MA, Grese TA, Neel DA, Wells KE, Ulm EH. Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors. Drug Metab Dispos. 2001;29(7):990-8.
Pyo SM, Maibach HI. Skin metabolism: relevance of skin enzymes for rational drug design. Skin Pharmacol Physiol. 2019;32(5):283-94. doi: 10.1159/000501732.
Lee DS, Park J, Kay KA, Christakis NA, Oltvai ZN, Barabási AL. The implications of human metabolic network topology for disease comorbidity. Proc Natl Acad Sci U S A. 2008;105(29):9880-5. doi: 10.1073/pnas.0802208105.
Testa B, Krämer SD. The biochemistry of drug metabolism--an introduction: part 1. Principles and overview. Chem Biodivers. 2006;3(10):1053-101. doi: 10.1002/cbdv.200690111.
Mekenyan OG, Dimitrov SD, Pavlov TS, Veith GD. A systematic approach to simulating metabolism in computational toxicology. I. The TIMES heuristic modelling framework. Curr Pharm Des. 2004;10(11):1273-93. doi: 10.2174/1381612043452596.
OECD (Q)SARs Application Toolbox. Available from: http://www.oecd.org/document/23/0,3343, en_2649_34379_33957015_1_1_1_1,00.html.
Koleva Y, Georgieva SF, Agova N. Probable skin metabolic activity of third-generation retinoids and newly synthesized derivatives of bexarotene. Bulg Chem Commun. 2020; 52:80-6. doi: 10.34049/bcc.52.A.310.
Agova N, Koleva Y, Georgieva S. Probable metabolic activity of bexarotene in the liver. Oxid Commun. 2018; 41(4):526–32.
Marill J, Idres N, Capron CC, Nguyen E, Chabot GG. Retinoic acid metabolism and mechanism of action: a review. Curr Drug Metab. 2003;4(1):1-10. doi: 10.2174/1389200033336900.
Email this article (Login required) 
